Biotech was starting to show signs of recovery after years of investor pullback—until new tariffs and economic uncertainty ...

When Australian biotech Telix Pharmaceuticals pulled a last-minute plug on its US public listing, it was yet another sign that the initial public offering (IPO) healthcare landscape was as ...

The market turbulence unleashed by President Donald Trump’s tariff policies will likely evaporate the trickle of biotech IPOs ...

Troy Ignelzi, CFO of Rapport Therapeutics (Nasdaq: RAPP), has ideas why the biotech IPO pipeline has been so muted. He points to the fact that it was only four years ago that 25 Massachusetts ...

“We were probably one of the lucky few that was able to go out last fall and have such a strong and successful IPO,” Bicara ...

The proposed transaction values VERAXA Biotech AG at USD 1.64 billion with expected gross cash proceeds up to USD 253 million held in trust by Voyager Acquisition Corp.

Omega Funds founder and managing director Otello Stampacchia isn’t afraid to tell it like he sees it.

Viela now plans to raise about $150 million in an IPO, according to a SEC filing from late August. More about Harmony Biosciences: The Pennsylvania-based biotech was founded in 2017 and makes a ...

“The strong start for biotech IPOs in 2014 reflects broad interest in the sector and the fact that biotech is outperforming the general markets,” CEO G. Steven Burrill said in the statement. “The ...

Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an IPO on the week of April 7th, IPO Scoop reports. The company plans to issue 2,700,000 shares at a price of $7.50-$8.50 ...

Though biotech IPOs have been quiet since 2021, industry experts believe that falling interest rates and favorable conditions for investments could reopen the IPO window for companies seeking ...

Going public with a valuation higher than $300 million may now be necessary to attract interest from institutional investors. A few times over the past two decades, a confluence of forces has ...